Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAX Corporation (NYSE: IMAX) files reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detail on its entertainment technology business, capital structure, and material events. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe the company’s convertible notes, credit facilities, and operating results.
Among its recent filings, IMAX has reported the entry into a Seventh Amended and Restated Credit Agreement, which increased its revolving borrowing capacity and set out leverage covenants, guarantees, and use of proceeds. The company has also filed an 8-K describing the issuance of 0.75% convertible senior notes due 2030, outlining interest terms, maturity, conversion rights, redemption conditions, and related capped call transactions intended to reduce potential dilution or offset certain cash payments upon conversion.
Investors reviewing IMAX filings can use this page to access documents that discuss the company’s financial obligations, including convertible debt, revolving credit facilities, and related covenants. Filings also reference IMAX’s global footprint, with systems operating in multiple countries and territories, and its listing on the New York Stock Exchange under the symbol IMAX.
Stock Titan’s SEC filings page for IMAX provides real-time access to new submissions from the EDGAR system, along with AI-powered summaries designed to explain the key terms and implications of complex filings. Users can quickly identify items related to financing transactions, results of operations, and other material corporate developments, and can locate information relevant to topics such as note conversion features, redemption provisions, and reporting covenants.
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting common shares in pre-planned transactions. He converted a total of 25,024 stock options into common shares at an exercise price of $31.40 per share and sold the same 25,024 shares in open-market trades at prices of $40.0034 and $40.2621 per share.
These option exercises were made under a Rule 10b5-1 Plan dated December 9, 2025 and relate to options granted in 2016 that are set to expire on June 7, 2026. Following the transactions, Mr. Gelfond directly holds 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,672,451, 231,562 and 765,002, respectively.
IMAX filed a Form 144 notice reporting a proposed sale of 12,987 shares of Common Stock acquired as compensation (stock options) via a cashless exercise / same-day sale. The filing also discloses prior sales by Richard Gelfond of 121,220 shares on 03/10/2026 for $4,860,837.15 and 12,037 shares on 04/02/2026 for $481,520.93.
IMAX CORP executive Daniel Manwaring, CEO of IMAX China Holding, reported several stock-based compensation movements on March 7, 2026. He exercised vested restricted share units, converting 7,409 and 4,666 units into the same number of common shares. He also received a new award of 5,072 restricted share units, each economically equivalent to one common share.
To cover tax obligations tied to these deliveries, the company withheld 4,790 common shares at $40.80 per share, a non‑market, tax-withholding disposition rather than an open-market sale. After these transactions, Manwaring holds 12,363 common shares and 21,816 restricted share units directly.
IMAX reported a Form 144 sale: Richard Gelfond sold 121,220 shares of Common Stock on 03/10/2026, reported with an aggregate value of $4,860,837.15. The filing lists Common shares on the NYSE and shows 53,993,017 shares cited with a 04/02/2026 date.
IMAX Corporation announced that CEO Richard Gelfond is on a temporary medical leave of absence while he receives treatment for pneumonia and recovers. During his absence, the company’s senior executives are handling day-to-day operations in coordination with Board Chair Darren Throop and with regular communication with the full Board.
The leadership team highlighted in the announcement includes CFO Natasha Fernandes, Chief Marketing Officer Anne Globe, Chief Legal Officer Rob Lister, and IMAX Theatres President Mark Welton, all of whom have significant tenure with the company. IMAX stated it is providing this update to avoid speculation about Gelfond’s absence from upcoming events and will offer further updates as appropriate.
IMAX Corporation’s major shareholder group led by Kevin Douglas filed Amendment No. 11 to its Schedule 13D to update its ownership and recent trading activity. The filing reports that, on March 16, 2026, the Douglas family and related trusts sold an aggregate of 568,000 IMAX common shares in a single block trade under Rule 144 at $37.82 per share.
The amendment details how this sale was allocated among the K&M Douglas Trust, James E. Douglas, III, two grantor trusts, four irrevocable descendant trusts, and related nonexempt trusts. Based on 53,993,017 IMAX common shares outstanding as of January 31, 2026, Kevin Douglas is reported as beneficially owning 8,351,373 shares, or 15.5% of the class, while Michelle Douglas holds 6,038,339 shares, or 11.2%. The K&M Douglas Trust holds 3,600,746 shares, or 6.7%. The group states that, aside from this March 16 block sale, no other transactions were made in the past 60 days and that only the filers have rights to dividends and sale proceeds on the reported shares.
IMAX CORP director and 10% owner Kevin Douglas–related entities reported sizable open-market sales of IMAX common stock. On March 16, 2026, accounts and trusts associated with Douglas sold a combined 568,000 shares at $37.82 per share.
After these transactions, Douglas and related entities still hold large positions, including 3,657,450 shares in a direct and joint account and additional shares through family trusts and Celtic Financial LLC. A footnote states the shares sold represent about 6.5% of his overall IMAX holdings and that his last sale of IMAX shares occurred in 2015.
StoneX Financial Inc. filed a Form 144 reporting proposed sales of Common Shares of IMAX Corporation on specified historic acquisition dates. The excerpt lists proposed sale amounts of 400,000 shares (acquired 12/07/2007), 80,000 shares (acquired 12/12/2007), and 120,000 shares (acquired 12/13/2007).
The filing shows broker/issuer contact details for StoneX Financial Inc. and includes an exchange reference NYSE with an apparent filing date of 03/16/2026. The document lists historic acquisition method as "acquired as a result of various open market purchases."
IMAX CORP Chief Executive Officer Richard L. Gelfond converted stock options into 121,220 common shares at an exercise price of $31.40 per share and on the same day sold 121,220 common shares at an average price of $40.0993 per share.
The conversion and sale were carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 765,002 common shares, along with remaining outstanding options over 1,697,475 shares and 231,562 restricted share units, indicating he retains a substantial equity stake.
IMAX CORP Chief Executive Officer Richard L. Gelfond reported compensation-related equity transactions in common shares. He acquired 196,964 common shares upon conversion of vested performance stock units tied to EBITDA performance conditions and 91,768 common shares from units tied to TSR performance conditions, both originally granted on January 2, 2023. To satisfy tax withholding obligations on these conversions, 159,670 common shares were withheld at a price of $40.80 per share. Following these transactions, he directly holds 765,002 common shares, with additional remaining outstanding option, restricted share unit and common share balances of 1,818,695 options, 231,562 restricted share units and 765,002 common shares, respectively.